- Home
- PRME vs CNNE Comparison
PRME vs CNNE Comparison
Compare PRME & CNNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | CNNE |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.4M | 609.0M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PRME | CNNE |
|---|---|---|
| Price | $3.26 | $13.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $7.56 | ★ $20.25 |
| AVG Volume (30 Days) | ★ 2.8M | 377.7K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 4.47% |
| EPS Growth | ★ 18.18 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,632,000.00 | ★ $499,700,000.00 |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $47.01 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 55.28 | 3.37 |
| 52 Week Low | $2.28 | $10.46 |
| 52 Week High | $6.94 | $21.96 |
Technical Indicators
Market Signals| Indicator | PRME | CNNE |
|---|---|---|
| Relative Strength Index (RSI) | 53.54 | 43.02 |
| Support Level | $3.16 | $12.59 |
| Resistance Level | $3.68 | $15.03 |
| Average True Range (ATR) | 0.27 | 0.52 |
| MACD | 0.02 | -0.13 |
| Stochastic Oscillator | 59.57 | 11.11 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.